EllisDon Expands Mandatory Type 2 Head Protection to All On-Site Personnel

Mississauga, ON, Jan. 06, 2026 (GLOBE NEWSWIRE) — EllisDon announced an enhancement of its safety requirements, as of January 1st, 2026, all personnel, including subcontractors and visitors, on EllisDon worksites must wear a CSA and/or ANSI Type 2 hard hat with a manufacturer-approved integrated (four-point) chin strap, properly adjusted and fastened. The hard hat Class must be appropriate for the hazards present and compliant […]

Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer

FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Jan. 06, 2026 (GLOBE NEWSWIRE) — Syncromune(R) Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T(TM), an in situ platform combination immunotherapy optimized for solid tumor cancers, today announced the appointment of Stephen P. Dale, M.D., as Chief Medical Officer. “Our priority at Syncromune is

Hallador Energy Appoints Barbara Sugg, Former CEO of Southwest Power Pool, to Join Board of Directors

(NASDAQ:HNRG), TERRE HAUTE, Ind., Jan. 06, 2026 (GLOBE NEWSWIRE) — Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today announced that its Board of Directors (the “Board”) has appointed Barbara Sugg to the Board, effective January 1, 2026. Ms. Sugg's appointment follows the resignation of David Hardie from the Board, effective January 1, 2026.

The Chefs’ Warehouse, Inc. to Participate in the ICR Conference

(NASDAQ:CHEF), RIDGEFIELD, Conn., Jan. 06, 2026 (GLOBE NEWSWIRE) — The Chefs' Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs'”), a premier distributor of specialty food products in the United States, the Middle East, and Canada, today announced that the Company will participate in a fireside chat at the ICR Conference in Orlando, FL on Tuesday,

Compass Therapeutics Provides Corporate Update

(NASDAQ:CMPX), The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), a

Skyworks Showcases Intelligent Connectivity Innovations at CES 2026

Skyworks Showcases Intelligent Connectivity Innovations at CES 2026 Company to Unveil Edge-IoT, Automotive, Audio, and Gaming Solutions GlobeNewswire January 06, 2026 LAS VEGAS, Jan. 06, 2026 (GLOBE NEWSWIRE) — Skyworks Solutions, Inc. (Nasdaq: SWKS) introduced the SKY66424-11, the industry's first highly integrated Wi-SUN(R)/LoRaWAN(R) RF front-end modules (FEM) designed for smart home and smart city applications

SpyGlass Pharma Appoints Jean-Frederic Viret as Chief Financial Officer

(NasdaqGM:CHRS), ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma(TM), a late-stage biopharmaceutical company, today announced the appointment of Jean-Frederic Viret, Ph.D., as the company's Chief Financial Officer (CFO). Dr. Viret brings over two decades of corporate finance experience in the life sciences industry, leading companies from early-stage clinical development through post-commercialization. At

Sysco to Announce Second Quarter Fiscal Year 2026 Financial Results on January 27

Sysco to Announce Second Quarter Fiscal Year 2026 Financial Results on January 27 GlobeNewswire January 06, 2026 HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE:SYY) will host a conference call and webcast to discuss its second quarter fiscal year 2026 financial results at 10 a.m. ET on Tuesday, January 27, 2026. All interested

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

(NASDAQ:ERAS), SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California.

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter GlobeNewswire January 06, 2026 ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC(TM) Magnetic Interventional Ablation Catheter. “FDA

Scroll to Top